Novo Nordisk said it will continue to pursue its intellectual property suit against Pfizer Inc over the insulin product Exubera, despite the decision of a US district judge to dismiss a preliminary motion against the US drugmaker. Earlier today US District Judge Leonard Sand refused to immediately block sales of Pfizer's Exubera product, saying the public's need for a 'new and less invasive treatment for diabetes' outweighed Novo Nordisk's claims that Pfizer is infringing on its patents. Novo Nordisk said it does not regard the ruling as impairing the strength of its underlying case, and noted that the ruling involves only one of the five patents at issue in the case.

Posted by GEN-ERIC at 12:10:42 am into the following categories: In The News

---

http://gen-eric.com/patents/htsrv/trackback.php/964

Name:

Email: (not displayed on this site)

Site/Url:

Comment text:

Allowed XHTML tags: <p, ul, ol, li, dl, dt, dd, address, blockquote, ins, del, a, span, bdo, br, em, strong, dfn, code, samp, kdb, var, cite, abbr, acronym, q, sub, sup, tt, i, b, big, small>

URLs, email, AIM and ICQs will be converted automatically.

Options:
Auto-BR (Line breaks become <br />)
Remember me (Set cookies for name, email & url)